72,000
Overdose Deaths in 20191
Developing Novel Therapies
For patients suffering from acute respiratory conditions.
Impact of Acute Respiratory Depression
30-50%
Mortality Rate for COVID-19 Patients Requiring Ventilation2
36%
Surgical Patients at High Risk of Respiratory Depression3
“There is an urgent need to develop novel agnostic therapeutic breathing stimulants to help patients suffering from acute respiratory depression. The simultaneous national health emergencies of Drug Overdose and COVID-19, plus the increasing population at high risk of a post-surgical respiratory event, is having a devastating impact on millions of patients and adding enormous cost to our healthcare system.“
– Herm Cukier, President & CEO
Development of Novel Compounds
Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning pivotal clinical trials in the US. With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential to dramatically improve the lives of those impacted by several of the Nation’s Top Health Emergencies; including the Drug Overdose Epidemic and COVID-19 Pandemic. ENA-001 will offer new treatment options for physicians, emergency responders, and care-givers addressing respiratory depression in multiple settings.
Who We Are
The Enalare team includes a very experienced management team, Board of Directors, world-renowned scientific advisors, and talented team members that are determined to advance our mission. This team brings decades of experience with top-tier biopharma companies, proven ability to develop and launch innovative products, and a track record of consistently creating significant shareholder value.